Physics and Applications of Laser Diode Chaos

An overview of chaos in laser diodes is provided which surveys experimental achievements in the area and explains the theory behind the phenomenon. The fundamental physics underpinning this behaviour and also the opportunities for harnessing laser diode chaos for potential applications are discussed. The availability and ease of operation of laser diodes, in a wide range of configurations, make them a convenient test-bed for exploring basic aspects of nonlinear and chaotic dynamics. It also makes them attractive for practical tasks, such as chaos-based secure communications and random number generation. Avenues for future research and development of chaotic laser diodes are also identified.Comment: Published in Nature Photonic

Predominant Dissemination of PVL-Negative CC89 MRSA with SCCmec Type II in Children with Impetigo in Japan

Background. The ratio of CA-MRSA in children with impetigo has been increasing in Japan. Methods. Antimicrobial susceptibilities of 136 S. aureus isolates from children with impetigo were studied. Furthermore, molecular epidemiological analysis and virulence gene analysis were performed. Results. Of the 136 S. aureus isolates, 122 (89.7%) were MSSA and 14 (10.3%) were MRSA. Of the 14 MRSA strains, 11 belonged to CC89 (ST89, ST91, and ST2117) and carried diverse types of SCCmec: type II (IIb: 3 strains; unknown subtype: 4 strains), type IVa (2 strains), and unknown type (2 strains). The remaining three strains exhibited CC8 (ST-8)-SCCmec type VIa, CC121 (ST121)-SCCmec type V, and CC5 (ST5)-nontypeable SCCmec element, respectively. None were lukS-PV-lukF-PV gene positive. Gentamicin- and clarithromycin-resistant strains were frequently found in both MRSA and MSSA. Conclusions. PVL-negative CC89-SCCmec type II strains are the most predominant strains among the CA-MRSA strains circulating in the community in Japan

Physician and Patient Preferences for Treatment of Anemia Associated with Chronic Kidney Disease in Japan: A Survey Including Best-Worst Scaling

Sari Mishina,1 Yuichiro Ito,1 Takumi Lee,1 Toshiaki Murofushi,2 Yoshiyuki Uetake,2 Tadao Akizawa3 1Astellas Pharma Inc, Tokyo, Japan; 2INTAGE Healthcare Inc, Tokyo, Japan; 3Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanCorrespondence: Sari Mishina, Astellas Pharma Inc, 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, Tel +81-3-3244-0294, Email [email protected]: Several treatment options are available for anemia associated with chronic kidney disease (CKD); however, there remains a lack of awareness of physician and patient preferences regarding these treatments. We aimed to explore physicians’ and patients’ perceptions and preferences regarding the management of anemia of CKD in Japan.Methods: A web-based survey, including best-worst scaling (BWS), was conducted with physicians who had treated ≥ 1 patient with anemia of CKD in the preceding year, and with patients with CKD who self-reported a clinical diagnosis of anemia of CKD or low hemoglobin levels. A three-step approach was used comprising cognitive interviews, a pilot survey, and a main survey. The BWS survey results were analyzed using multinomial logit and hierarchical Bayesian models.Results: The survey was completed by 906 participants: 103 patients (average age 60.6 years; 77.7% male) and 803 physicians (166 nephrologists, 214 cardiologists, 137 diabetologists, and 286 general internists). Almost all (96.0%) physicians surveyed considered anemia of CKD to be an important condition to treat. Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors had the highest treatment satisfaction among physicians, whereas patients had the highest satisfaction with both erythropoietin-stimulating agent therapy and HIF-PH inhibitors. Approximately one-third (35.9%) of patients surveyed indicated that they were receiving treatment. When comparing the relative importance of attributes and levels, physicians favored efficacy (particularly improvement in hemoglobin levels), whereas patients favored safety (particularly a lower rate of severe adverse events).Conclusion: Although a majority of physicians consider treatment of CKD-related anemia important, differences in the perceptions and usage of medications exist between medical specialties. Preferences for the management of anemia of CKD vary between physicians and patients; therefore, patient involvement in treatment decisions may help optimize outcomes.Keywords: anemia, best-worst scaling, chronic kidney disease, erythropoiesis-stimulating agents, hypoxia-inducible factor prolyl hydroxylase inhibitors, treatment preferenc

Japanese haemodialysis anaemia management practices and outcomes (1999–2006): results from the DOPPS

Background. Japanese haemodialysis (HD) patients not only have a very low mortality and hospitalization risk but also low haemoglobin (Hb) levels. Internationally, anaemia is associated with mortality, hospitalization and health-related quality of life (QoL) measures of HD patients

2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report

Improving Global Outcomes (KDIGO) Clinical Practice Guideline on Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD) 2009 provided recommendations on the detection, evaluation, and treatment of CKD-MBD in patients CKD who are and are not undergoing dialysis. Because of the accumulation of evidence since this initial publication, the CKD-MBD Guideline underwent a selective update in 2017. In April 2018, KDIGO convened a CKD-MBD Guideline Implementation Summit in Japan with the key objective to discuss various barriers to the uptake and implementation of the CKD-MBD Guideline in 8 Asian countries/regions. These countries/regions were comparable according to their high-to-middle economic ranking assigned by the World Bank. The discussion took into account the availability of CKD-MBD medication therapies and government health policies that may influence reimbursement and practice patterns in the region. Most importantly, Summit participants developed a framework of multifaceted strategies aimed at overcoming barriers to guideline implementation. The Summit attendees suggested a shared decision-making approach between clinicians and patients in CKD-MBD management, as well as individualized care based on the treatment risk-benefit ratio. The Summit participants also discussed how KDIGO, as a guideline development organization, may work in partnership with local and national nephrology societies to provide education and facilitate implementation of the guideline by clinicians. The conclusions drawn from this Summit in Asia may serve as an important guide for other regions to follow

The LiteBIRD mission to explore cosmic inflation

LiteBIRD, the next-generation cosmic microwave background (CMB) experiment, aims for a launch in Japan’s fiscal year 2032, marking a major advancement in the exploration of primordial cosmology and fundamental physics. Orbiting the Sun-Earth Lagrangian point L2, this JAXA-led strategic L-class mission will conduct a comprehensive mapping of the CMB polarization across the entire sky. During its 3-year mission, LiteBIRD will employ three telescopes within 15 unique frequency bands (ranging from 34 through 448 GHz), targeting a sensitivity of 2.2 µK-arcmin and a resolution of 0.5º at 100 GHz. Its primary goal is to measure the tensor-toscalar ratio r with an uncertainty δr = 0.001, including systematic errors and margin. If r ≥ 0.01, LiteBIRD expects to achieve a > 5σ detection in the ℓ = 2–10 and ℓ = 11–200 ranges separately, providing crucial insight into the early Universe. We describe LiteBIRD’s scientific objectives, the application of systems engineering to mission requirements, the anticipated scientific impact, and the operations and scanning strategies vital to minimizing systematic effects. We will also highlight LiteBIRD’s synergies with concurrent CMB projects.This work is supported in Japan by ISAS/JAXA for Pre-Phase A2 studies, by the acceleration program of JAXA research and development directorate, by the World Premier International Research Center Initiative (WPI) of MEXT, by the JSPS Core-to-Core Program of A. Advanced Research Networks, and by JSPS KAKENHI Grant Numbers JP15H05891, JP17H01115, and JP17H01125. The Canadian contribution is supported by the Canadian Space Agency. The French LiteBIRD phase A contribution is supported by the Centre National d’Etudes Spatiale (CNES), by the Centre National de la Recherche Scientifique (CNRS), and by the Commissariat à l’Energie Atomique (CEA). The German participation in LiteBIRD is supported in part by the Excellence Cluster ORIGINS, which is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy (Grant No. EXC-2094 - 390783311). The Italian LiteBIRD phase A contribution is supported by the Italian Space Agency (ASI Grants No. 2020-9-HH.0 and 2016-24-H.1-2018), the National Institute for Nuclear Physics (INFN) and the National Institute for Astrophysics (INAF). Norwegian participation in LiteBIRD is supported by the Research Council of Norway (Grant No. 263011) and has received funding from the European Research Council (ERC) under the Horizon 2020 Research and Innovation Programme (Grant agreement No. 772253 and 819478). The Spanish LiteBIRD phase A contribution is supported by MCIN/AEI/10.13039/501100011033, project refs. PID2019-110610RB-C21, PID2020-120514GB-I00, PID2022-139223OB-C21 (funded also by European Union NextGenerationEU/PRTR), and by MCIN/CDTI ICTP20210008 (funded also by EU FEDER funds). Funds that support contributions from Sweden come from the Swedish National Space Agency (SNSA/Rymdstyrelsen) and the Swedish Research Council (Reg. no. 2019-03959). The UK LiteBIRD contribution is supported by the UK Space Agency under grant reference ST/Y006003/1 - "LiteBIRD UK: A major UK contribution to the LiteBIRD mission - Phase1 (March 25)" The US contribution is supported by NASA grant no. 80NSSC18K0132. TG acknowledges the support of JSPS KAKENHI Grant Number 22K14054

Heterogeneous Earth’s mantle drilled at an embryonic ocean

Mantle processes control plate tectonics and exert an influence on biogeochemical cycles. However, the proportion of mantle sampled in-situ is minimal, as it is buried beneath igneous crust and sediments. Here we report the lithological characteristics of two mantle sections from an embryonic ocean drilled by the International Ocean Discovery Program (IODP) in the Tyrrhenian Sea. Contrary to the mantle drilled at Mid Ocean Ridges (MORs) and hyperextended passive margins, our findings reveal exceptionally heterogeneous and fertile mantle lithologies, ranging from fertile lherzolites to depleted harzburgites and dunites, interlayered with pyroxenites. Plagioclase- and clinopyroxene-rich layers, hydrous potassic magmatic veins, and mafic intrusions indicate substantial mantle refertilization and delayed inception of magmatic crust. We propose that magma-poor rifts do not require a chemically depleted mantle, too refractory to melt. Deep lithospheric processes such as mantle refertilization and prolonged lithospheric thinning delayed melt focusing and the formation of a steady-state spreading center